|
Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes
|
Research Initiative
|
CDC
|
NIDDK
|
This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of CDC and NIDDK to conduct vital health services and health policy research related to diabetes prevention and care.
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process.
|
|
NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NHLBI, NIBIB, NIEHS
|
The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government and industry with diverse interests.
|
|
NCI/CDC Cooperative Agreements for Cancer Control Activities in Low and Middle Income Countries
|
Other
|
CDC
|
NCI
|
NCI is partnering with CDC in Kenya and Indonesia to fund cancer control activities through the CDC cooperative agreement, via an interagency agreement between NCI/CGH and CDC. The activities that will take place under this agreement include cancer registry strengthening and related cancer control activities.
|
|
NCI/FDA Federal Investigator Registry of Biomedical Information Research Data (FIREBIRD)
|
Resource Development
|
FDA
|
NCI
|
An agreement has been reached by the U.S. Food and Drug Administration and the National Cancer Institute to manage and share information about clinical investigators using the Federal Investigator Registry of Biomedical Information Research Data, or FIREBIRD, system. Drug makers are encouraged to also submit information about investigators electronically to the new registry. FIREBIRD is the first module of an expected suite of software programs that will comprise a system called the Clinical Research Information Exchange (CRIX). CRIX is intended to support the biomedical and biopharmaceutical research community by streamlining the document and data exchange process. The resulting reduction of paperwork is expected to increase the efficiency and lower the cost of conducting clinical trials.
|
|
NCI/FDA Memorandum of Understanding for Drug Related Information
|
Resource Development
|
FDA
|
NCI
|
The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the U.S. Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus.
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
NCI
|
This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the NCI (Office of Cancer Clinical Proteomics Research) and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development.
|
|
Nested Case-Controlled Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners
|
Research Initiative
|
CDC
|
NCI
|
A retrospective cohort mortality and nested case-control study of about 12,315 non-metal miners (278,041 person-years) to investigate risk of lung cancer in relation to quantitative measures of exposure to diesel exhaust.
|
|
Neural Interfaces Conference
|
Meeting/ Workshop
|
FDA
|
NIBIB, CSR, NEI, NIA, NICHD, NIDCD, NINDS
|
The Neural Interfaces research community consists of investigators, supported by grants or contracts, who are working in areas that include functional neuromuscular/electrical stimulation, auditory prosthesis, cortical prosthesis, neuromodulation, microelectrode array technology, brain computer/machine interfaces and other related areas. Conferences were held in 2010 and 2012 and most recently in June 2014.
|
|
Newborn Drug Development Planning Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NHLBI, NLM
|
This collaboration''s primary responsibility is administering, contracting, and monitoring studies to develop Investigational new drug application data for potential label modification.
|